Get the Stockscreener App
1.37
4.86%
-0.07
After Hours:
1.65
0.28
+20.44%
Dare Bioscience Inc stock is traded at $1.37, with a volume of 1.16M.
It is down -4.86% in the last 24 hours and down -34.45% over the past month.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$1.44
Open:
$1.43
24h Volume:
1.16M
Relative Volume:
4.51
Market Cap:
$20.52M
Revenue:
$1.16M
Net Income/Loss:
$-12.02M
P/E Ratio:
-1.3197
EPS:
-1.0381
Net Cash Flow:
$-10.16M
1W Performance:
+3.01%
1M Performance:
-34.45%
6M Performance:
-19.41%
1Y Performance:
-35.07%
1-Day Range:
$1.31
$1.4572
1-Week Range:
$1.31
$1.4675
52-Week Range:
$1.13
$3.78
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
1.37 | 21.57M | 1.16M | -12.02M | -10.16M | -1.0381 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dare Bioscience Inc Stock (DARE) Latest News
Dare Bioscience Q2 Results: Net loss narrows to $3.0M, cash falls - scanx.trade
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances - The Manila Times
Daré Bioscience launches Flora Sync, its first directly commercialized product - Stock Titan
Dare Bioscience Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Transcript : Daré Bioscience, Inc.Special Call - marketscreener.com
Dare Bioscience Inc (DARE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dare Bioscience (DARE.US) will release its earnings report after market close on August 13. - Moomoo
Dare Bioscience (DARE) Eases 0.75% to $1.33: Stock Hovers Between Key Support and ResistanceHedge Fund Exposure - dars.gov.et
Daré Bioscience to Host Second Quarter 2026 Financial - GlobeNewswire
Dare Bioscience Inc (DARE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dare Slides on MyMenopauseRx Hookup - Baystreet.ca
Daré Bioscience partners with menopause telehealth platform By Investing.com - Investing.com Nigeria
Daré Bioscience partners with menopause telehealth platform - Investing.com
Daré Bioscience Expands Access Options for DARE to PLAY™ - GlobeNewswire
Daré Bioscience partners with MyMenopauseRx to ... - pluang.com
DARE|Dare Bioscience Inc|Price:1.330|Chg%:+0.050 - TradingKey
Dare Bioscience Inc (DARE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dare Bioscience, Inc. Revenue Breakdown – NASDAQ:DARE - TradingView
Dare Bioscience Inc (DARE) Income Statement - TradingKey
Dare Bioscience Inc (DARE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dare Bioscience Inc (DARE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dare Bioscience Inc (DARE) Cash Flow - TradingKey
Dare Bioscience Inc (DARE) Institutional Confidence - TradingKey
Dare Bioscience Market Sentiment - Benzinga España
DARE|Dare Bioscience Inc|Price:1.280|Chg%:+0.020 - TradingKey
Daré Bioscience Releases New Investor Corporate Presentation - TipRanks
Dare Bioscience Inc (DARE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
Daré Bioscience launches virtual bus tour webin... - Pluang
Daré Bioscience Launches “Across the U.S.” Virtual Bus Tour Webinar Series for Investors - Quiver Quantitative
Daré Bioscience Launches Nationwide Virtual Bus Tour - GlobeNewswire
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities - The Manila Times
Daré Bioscience Files 8-K Notice of Delisting or Failure to Satisfy Nasdaq Listing Requirements – July 2026 - Minichart
Daré Bioscience Faces Nasdaq Listing Compliance Challenges - TipRanks
Dare Bioscience Received Notice of Delisting - TradingView
Daré Bioscience Advances DARE-HPV Trial, Raising New Questions for HPV Treatment Investors - TipRanks
Dare Bioscience (DARE) Shares Decline 3.38% as Stock Holds Above Key Support at $1.9BPI Bear Correction - dars.gov.et
Daré Bioscience at Virtual Investor Closing Bell: shift to sales By Investing.com - Investing.com Canada
DARE: Commercial launches and clinical milestones in women's health drive growth and value through 2027 - TradingView
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025 - 富途牛牛
Daré Bioscience Updates Investors With New Presentation - TipRanks
[8-K] Dare Bioscience, Inc. Reports Material Event - Stock Titan
Dare Bioscience Company Profile & Introduction - Moomoo
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event - The Manila Times
Price to sales forward of Dare Bioscience, Inc. – NASDAQ:DARE - TradingView
DARE Technical Analysis & Stock Price Forecast - Intellectia AI
Daré Bioscience launches prescription-free vaginal probiotic capsule for microbiome support - Contemporary OB/GYN
Price to earnings forward of Dare Bioscience, Inc. – NASDAQ:DARE - TradingView
Dare Bioscience (DARE) director receives 23,696 RSUs in lieu of cash pay - Stock Titan
Dare Bioscience (DARE) director awarded 30,805 RSUs as board compensation - Stock Titan
Dare Bioscience (DARE) grants 38,862 RSUs to board director - Stock Titan
Dare Bioscience Inc Stock (DARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):